Table 3.

Baseline characteristics, laboratory results and clinical outcomes of 455 patients categorised by vaccination status in 2022

	0 or 1 dose	2 or 3 doses	p-value*
N	90	365
Age (years)	68.5 (41.0, 82.0)	71.0 (50.0, 82.0)	0.47
Male	41 (46.6%)	172 (48.0%)	0.81
Vaccination status			<0.001
Unvaccinated	77 (85.6%)	0 (0.0%)
1 dose	13 (14.4%)	0 (0.0%)
2 doses	0 (0.0%)	333 (91.2%)
3 doses	0 (0.0%)	32 (8.8%)
Vaccine type			0.39
Astra Zeneca (Vaxzevria)	5 (38.5%)	173 (50.6%)
mRNA (Pfizer-BioNTech or Moderna)	8 (61.5%)	169 (49.4%)
Days from symptom onset to admission	4.0 (2.0, 8.0)	4.0 (2.0, 8.0)	0.91
Diabetes	23 (25.8%)	140 (38.4%)	0.027
BMI (kg/m2)	30.3 (25.6, 37.3)	28.2 (25.1, 33.8)	0.22
Outcomes
Venous thrombosis	2 (2.3%)	7 (2.0%)	0.85
Arterial thrombosis	3 (3.3%)	18 (4.9%)	0.52
Assisted ventilation	30 (33.3%)	60 (16.4%)	<0.001
Clinical deterioration	35 (38.9%)	72 (19.7%)	<0.001
Death caused by COVID-19	13 (15.1%)	14 (3.9%)	<0.001
Laboratory findings
Haemoglobin (g/L), mean (SD)	133.6 (17.6)	132.4 (20.3)	0.61
Neutrophils (×109/L)	4.5 (3.3, 7.6)	4.8 (3.4, 6.8)	0.91
Lymphocytes (×109/L)	0.9 (0.6, 1.4)	1.0 (0.7, 1.6)	0.091
Platelets (×109/L)
Creatinine (mmol/L)	76.0 (58.0, 103.0)	84.0 (63.0, 116.0)	0.097
Ferritin (ug/L)	631.0 (264.0, 1406.0)	306.0 (123.0, 621.0)	<0.001
LDH (units/L)	327.0 (246.0, 486.0)	283.0 (219.5, 375.5)	0.004
CRP (mg/L)	62.0 (18.0, 104.0)	30.0 (9.0, 88.0)	0.011
D-dimer (mg/L FEU)	1.2 (0.7, 2.1)	0.8 (0.5, 1.8)	0.011
Fibrinogen (g/L)	5.1 (4.5, 6.5)	4.6 (3.9, 6.2)	0.33

mRNA Messenger RNA, BMI Body mass index, LDH Lactate dehydrogenase, CRP C-reactive protein

^*All p-values are univariate; boldened values signify p < 0.05

Data are n (%), and median (interquartile range, IQR), unless specified otherwise